We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glioblastoma Growth Inhibitor Readily Passes the Blood-Brain Barrier

By LabMedica International staff writers
Posted on 12 Apr 2010
Print article
A low molecular weight drug that inhibits the cyclin-dependent kinases 4 and 6 (cdk4/6) has been shown to prevent the growth of glioblastoma brain cancer cells both in vitro and in a mouse model.

While the drug, PD-0332991, is currently being evaluated in clinical trials for otherwise untreatable teratomas as well as multiple myeloma and breast cancer, the current report is the first on its potential effectiveness against glioblastoma.

Investigators at the University of California, San Francisco (USA) and Georgetown University (Washington, DC, USA) tested the drug on 21 different cell cultures derived from the tumors of patients with glioblastoma. They reported in the March 30, 2010, online edition of the journal Cancer Research, that 16 of the cultures stopped growing. The remaining five, all of which lacked the gene for the tumor-suppressor protein retinoblastoma (Rb), were not affected by the drug.

In the animal experiment, the investigators implanted three different strains of human glioblastoma directly into the brains of mice, which were then treated with PD-0332991. Results indicated that the drug effectively reached the intracranial tumors, and that the tumors did not grow as long as the mice continued to receive the drug. However, the animals quickly succumbed to the cancer if drug treatment was stopped.

"What is especially encouraging about this agent is that we found it can easily pass through the blood-brain barrier and access glioblastoma, and that there is already a simple test available for screening glioblastoma patients in advance to see whether or not they should be responsive to this therapy,” said contributing author Dr. C. David James, professor of neurological surgery at the University of California, San Francisco. "We do not know how well this agent will perform in patients with glioblastoma, but in the mice we studied, we saw very impressive, durable effect that was sustained as long as therapy was administered.”

Related Links:
University of California, San Francisco
Georgetown University


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
ELISA System
ABSOL HS DUO
New
Cortisol Rapid Test
Finecare Cortisol Rapid Quantitative Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.